Table 4.
Clinicopathological Characteristics of GIST Patients According to the KIT and PDGFRA Mutation Status
| Clinicopathologic Parameters (Total Samples n = 46) | % (n) | KIT | PDGFRA | ||||
|---|---|---|---|---|---|---|---|
| Wild Type [% (n)] | Mutation [% (n)] | p | Wild Type [% (n)] | Mutation [% (n)] | p | ||
| Gender | 0.29 | 0.57 | |||||
| Female | 56.5 (26) | 42.3 (11) | 57.7 (15) | 76.9 (20) | 23.1 (6) | ||
| Male | 43.5 (20) | 30 (6) | 70 (14) | 75 (15) | 25 (5) | ||
| Age | 0.02 | 0.13 | |||||
| >50 | 87 (40) | 30 (12) | 70 (28) | 80 (32) | 20 (8) | ||
| ≤50 | 13 (6) | 83.3 (5) | 16.7 (1) | 50 (3) | 50 (3) | ||
| Tumor type | 0.22 | 0.51 | |||||
| Primary | 84.8 (39) | 33.3 (13) | 66.7 (26) | 76.9 (30) | 23.1 (9) | ||
| Metastatic | 15.2 (7) | 57.1 (4) | 42.9 (3) | 71.4 (5) | 28.6 (2) | ||
| Tumor location | 0.07 | 0.08 | |||||
| Stomach | 43.5 (20) | 30 (6) | 70 (14) | 85 (17) | 15 (3) | ||
| Small intestine | 34.8 (16) | 25 (4) | 75 (12) | 81.3 (13) | 18.8 (3) | ||
| Large intestine | 4.3 (2) | 100 (2) | 0 | 0 | 100 (2) | ||
| Esophagus | 4.3 (2) | 100 (2) | 0 | 50 (1) | 50 (1) | ||
| Omentum-periton | 4.3 (2) | 50 (1) | 50 (1) | 0 | 100 (2) | ||
| Others | 8.7 (4) | 50 (2) | 50 (1) | 100 (4) | 0 | ||
| Histological type | 0.67 | 0.91 | |||||
| Spindle | 82.6 (38) | 39.5 (15) | 60.5 (23) | 76.3 (29) | 23.7 (9) | ||
| Mixed type | 10.9 (5) | 20 (1) | 80 (4) | 80 (4) | 20 (1) | ||
| Epitheloid | 6.5 (3) | 33.7 (1) | 66.7 (2) | 66.7 (2) | 33.3 (1) | ||
| Tumor size | 0.11 | 0.24 | |||||
| <5.25 cm | 50 (23) | 26.1 (6) | 73.9 (17) | 82.6 (19) | 17.4 (4) | ||
| ≥5.25 cm | 50 (23) | 47.8 (11) | 52.2 (12) | 69.6 (16) | 30.4 (7) | ||
| Mitosis/50 HPF | 0.23 | 0.44 | |||||
| <5 | 60.9 (28) | 42.9 (12) | 57.1 (16) | 78.6 (22) | 21.4 (6) | ||
| ≥5 | 39.1 (18) | 27.8 (5) | 72.2 (13) | 72.2 (13) | 27.8 (5) | ||
| Risk group | 0.51 | 0.48 | |||||
| High | 67.4 (31) | 35.5 (11) | 64.5 (20) | 74.2 (23) | 25.8 (8) | ||
| Low | 32.6 (15) | 40 (6) | 60 (9) | 80 (12) | 20 (3) | ||
| CD117 | |||||||
| Negative | 0 | 0 | 0 | 0 | 0 | ||
| Positive | 100 (46) | 37 (17) | 63 (29) | 76.1 (35) | 23.9 (11) | ||
| CD34 | 0.23 | 0.02 | |||||
| Negative | 26.1 (12) | 50 (6) | 50 (6) | 50 (6) | 50 (6) | ||
| Positive | 73.9 (34) | 32.4 (11) | 67.6 (23) | 85.3 (29) | 14.7 (5) | ||
| SMA | 0.17 | 0.49 | |||||
| Negative | 41.3 (19) | 26.3 (5) | 73.7 (14) | 78.9 (15) | 21.1 (4) | ||
| Positive | 58.7 (27) | 44.4 (12) | 55.6 (15) | 74.1 (20) | 25.9 (7) | ||
| S-100 | 0.62 | 0.23 | |||||
| Negative | 58.7 (27) | 37 (10) | 63 (17) | 70.4 (19) | 29.6 (8) | ||
| Positive | 41.3 (19) | 36.8 (7) | 63.2 (12) | 84.2 (16) | 15.8 (3) | ||
| Desmin | 0.63 | 0.37 | |||||
| Negative | 82.6 (38) | 36.8 (14) | 63.2 (24) | 73.7 (28) | 26.3 (10) | ||
| Positive | 17.4 (8) | 37.5 (3) | 62.5 (5) | 87.5 (7) | 12.5 (1) | ||
| Ki-67 | 0.59 | 0.44 | |||||
| Negative | 69.6 (32) | 37.5 (12) | 62.5 (20) | 78.1 (25) | 21.9 (7) | ||
| Positive | 30.4 (14) | 35.7 (5) | 64.3 (9) | 71.4 (10) | 28.6 (4) | ||
Tumors with <10% of positive cells were considered as negative for all markers except DOG1. Diffuse- or focal-stained specimens were accepted as positive.